Promoting Excellence : Commonly Used Drugs for Symptoms of Patients with Chronic Kidney Disease

Name:
Renal Palliative Care Initiative: Commonly Used Drugs for Symptoms of Patients with Chronic Kidney Disease

Description:
This chart references the commonly prescribed drugs used to treat the symptoms accompanying end stage renal disease.

Category:
Clinical Care Tools - Symptom Management

Source:
Renal Palliative Care Initiative
Baystate Medical Center
759 Chestnut Street S2669
Springfield, MA 01199

Contact:
Michael Germain, M.D.
Michael.germain@bhs.org

How the grantee used this instrument:
This protocol was made available at the clinics and renal unit nursing stations.

Keywords:
esrd, end stage renal disease, dialysis, kidney disease, symptom assessment, medications

To use this tool:
You may print and copy this tool for your own use from this site. Please credit source.

References:

1. Altamura AC, Moro AR, Percudani M. "Clinical pharmacokinetics of fluoxetine." Clinical Pharmacokin, 1994;26:201-214.
2. Anderson RJ, Gambertogolio JG, Schrier RW. "Clinical Use of Drugs in Renal Railure." Charles C Thomas, Springfield, IL. 1976
3. Aronoff GR, Berns JS, Brier ME, Gloper TA, Morrison G, Singer I, Swan SK, Bennett WM. "Drug Prescribing in Renal Failure Dosing Guidelines for Adults," Fouth Edition. 1999: American College of Physicians - American Society of Internal Medicine, ISBN 0-943126-76-2.
4. Borison RL. "Amantadine-induced psychosis in a geriatric patient with renal disease." American Journal of Psychiatry, 1979;136:111-112.
5. Brater DC. "Drug Dosing in Renal Failure in Therapy in Nephrology and Hypertension," A companion to Brenner and Rector's THE KIDNEY, 641-653.
6. Davies G, Kingswood C, Street M. "Pharmacokinetics of opioids in renal dysfunction." Clinical Pharmacokinet, 1996;31:410-422.
7. Dheenan S, Venketesan J, Grubb BP, Henrich WL. "Effect of sertraline hydrochloride on dialysis hypotension." American Journal of Kidney Diseases, 1998;31:624-630.
8. Facca A, Sanchez-Ramos J: "High-dose pergolide monotherapy in the treatment of severe levodopa-induced dyskenisias (letter)." Movement Disorders, 1996;11:327-329.
9. Garzone PD, Kroboth PD. "Pharmacokinetics of the newer Benzodiazepines." Clinical Pharmacokinet, 1994:16:337-364.
10. Hoppmann RA, Peden JG, Ober SK. "Central nervous system side effects of non-steroidal anti-inflammatory drugs." Archives of Internal Medicine, 1991;151:1309-1313.
11. Inturrisi CE. "Disposition of narcotics in patients with renal disease." American Journal of Medicine, 1977;62:528-529.
    Lam YWF, Banerji S, Hatfield C, Talbert RL. "Principles of drug administration in renal insufficiency." Clinical Pharmacokinet, 1997;32:30-57.
12. Laurijssens BE, Greenblatt DJ. "Pharmacokinetic-pharmacodynamic relationships for benzodiazepines." Clinical Pharmacokinet, 1996;30:52-76.
13. Levy NB. "Psychiopharmacology in patients with renal failure." International Journal of Psychiatry in Medicine, 1990;20:325-334.
14. Ochs HR, Greenblatt DJ, Labedzki L, Smith RB. "Alprazolam kinetics in patients with renal insufficiency." Journal of Clinical Psychopharmacol, 1986;6:292-294.
15. Olyaei AJ, deMattos AM, Bennet WM. "Prescribing drugs in Renal Disease in Management of the patient with renal failure." 2606 - 2653.
16. Preskorn SH. "Clinically relevant pharmacology of selective serotonin reuptake inhibitors." Clinical Pharmacokinet, 1997;32 (S1):1-21.
17. Product Information: Ambien ®, zolpidem. G.D.Searle and Company, Skokie, IL, 1999.
18. Product Information: Halcion ®, triazolam. UpJohn Laboratories, Kalamazoo, MI, 1994.
19. Product Information: Poxicodone ™, oxycodone. Roxane Laboratories, Innc. Columbus, OH (PI revised 8/2000)
20. Product Information: Sonata ®, zaleplon. Wyeth Laboratories, Philadelphia, PA, 1999.
21. Product Information: Stelazine ®, trifluoperazine SmithKline & French, Philadelphia, PA 1995.
22. Product Information: Talacen ®, pentazocine and acetaminophen. Sanofi-Synthelabo Inc, New York, NY, 1999.
23. Product Information: Thorazine ®, chlorpromazine. SmithKline Beecham Pharmaceuticals, Philadelphia, PA (PI revised 4/99).
24. Product Information: Zyprexa ®, olanzapine. Eli Lilly and Company, Indianapolis, IN (PI revised 10/2000).
25. Rubin A, Lemberger L, Dhahir P: "Physiologic disposition of pergolide." Journal of Clinical Pharmacology, 1981;30:258-265.
26. Sandoz M, Vandel S, Vandel B, Bonin B, Hory B, et al. Metabolism of amitriptyline in patients with chronic renal failure. European Journal of Clinical Pharmacology, 1984:26:227-232.
27. Schmith VD, Piraino B, Smith RB, Kroboth PD. "Alprazolam in end stage renal disease:" Journal of Clinical Pharmacology, 1991;31:571-579.
28. Schwenk MH, Verga MA, Wagner JD. "Hemodialyzability of sertraline." Clinical Nephrology, 1995;44:121-124.
29. Wad N, Guenat C, Kramer G. "Carbamazepine: detection of another metabolite in serum, 9 hydroxymethyl-10-carbamoyl acridan." Theraputic Drug Monitor, 1997;19:314-317
30. Wagner BKJ, O'Hara DA. "Pharmacokinetics and pharmacodynamics of sedatives and analgesics in the treatment of agitated critically ill patients." Clinical Pharmacokinet, 1997;33:426-453.
31. Wong MO, Eldon MA, Keane WF, Turck D Bockbrader HN, et al. "Disposition of gapapentin in anuric subjects on hemodialysis." Journal of Clinical Pharmacology, 1995;35:622-626.
32. Wood KA, Harris MJ, Morreale A, Rizos AL. "Drug-induced psychosis and depression in the elderly." Psychology Clinics of North America 1988;11:167193
33. Bateman DN, "Clinical pharmacokinetics of metoclopramide." Clinical Pharmacokinet, 1983:8:523-9

To view this tool:
Left click on the download link to view the PDF document in your Web browser. Right-click on the download link to save the document to your computer.
PDF 265 KB / 2 pages (Viewing PDF files requires downloading and installation of the free Adobe Acrobat Reader.)

Posted April 2004

Baystate Medical Center overview page

# BMC16, type:symptom_management

Promoting Excellence in End-of-Life Care is a national program of The Robert Wood Johnson Foundation dedicated to long-term changes in health care institutions to substantially improve care for dying people and their families. Visit PromotingExcellence.org for more resources.